Clinical Trial Update: A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating certolizumab pegol for reducing anterior uveitis flares in patients with axial spondyloarthritis and a history of AU, completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anterior Uveitis
• Axial Spondyloarthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Axial Spondyloarthritis (axSpA), Anterior Uveitis (AU) | Phase 4 | Status: COMPLETED | Results posted: 2020-12-31